Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.42 |
| ▸ | SRC | P12931 | 8/20 | 0.39 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | PARP1 | P09874 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2386707 | 1.00 | NR1H2 (0.42) | NR1H2SRCABCB1MEN1KMT2A | |
| SCHEMBL21286125 | 1.00 | NR1H2 (0.42) | NR1H2SRCABCB1MEN1KMT2A | |
| SCHEMBL1241324 | 1.00 | NR1H2 (0.42) | NR1H2SRCABCB1MEN1KMT2A | |
| SCHEMBL19964151 | 1.00 | NR1H2 (0.42) | NR1H2SRCABCB1MEN1KMT2A | |
| SCHEMBL142689 | 1.00 | NR1H2 (0.42) | NR1H2SRCABCB1MEN1KMT2A | |
| SCHEMBL139880 | 1.00 | NR1H2 (0.42) | NR1H2SRCABCB1MEN1KMT2A | |
| SCHEMBL20312947 | 1.00 | NR1H2 (0.42) | NR1H2SRCABCB1MEN1KMT2A | |
| SCHEMBL1372634 | 1.00 | NR1H2 (0.42) | NR1H2SRCABCB1MEN1KMT2A | |
| SCHEMBL30868937 | 0.97 | NR1H2 (0.40) | NR1H2SRCABCB1MEN1KMT2A | |
| SCHEMBL6577745 | 0.92 | NR1H2 (0.41) | NR1H2SRCMEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3401315-A1 | FXR RECEPTOR MODULATOR, PREPARATION METHOD THEREFOR, AND USES THEREOF | Guangzhou Henovcom Bioscience Co. Ltd. (CN) | 2018-11-14 | — | — | EP | disclosed |
| US-9546173-B2 | Substituted pyrrolo[3,4-d]pyrimidines as kinase inhibitors | NOVARTIS AG (CH) | 2017-01-17 | — | — | US | disclosed |
| EP-2897961-B1 | DIHYDROPYRROLIDINO-PYRIMIDINES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2016-10-26 | — | — | EP | disclosed |
| US-20150274733-A1 | DIHYDROPYRROLIDINO-PYRIMIDINES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2015-10-01 | — | — | US | disclosed |
| EP-2897961-A1 | DIHYDROPYRROLIDINO-PYRIMIDINES AS KINASE INHIBITORS | Novartis AG (CH) | 2015-07-29 | — | — | EP | disclosed |
| US-8969383-B2 | Picolinamide derivatives as TTX-S blockers | RAQUALIA PHARMA INC. (JP) | 2015-03-03 | — | — | US | disclosed |
| US-20140296237-A1 | PICOLINAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC (JP) | 2014-10-02 | — | — | US | disclosed |
| EP-2493877-B1 | PYRIMIDINE COMPOUNDS AS DELTA OPIOID RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2014-09-17 | — | — | EP | disclosed |
| US-8809380-B2 | Picolinamide derivatives as TTX-S blockers | RAQUALIA PHARMA INC. (JP) | 2014-08-19 | — | — | US | disclosed |
| US-8754107-B2 | Aminopyrrolidines as chemokine receptor antagonists | ABBVIE INC. (US) | 2014-06-17 | — | — | US | disclosed |
| US-5972984-A | LOW MOLECULAR WEIGHT PEPTIDYL COMPOUNDS THAT DO NOT HAVE A THIOL MOIETY. | MERCK & CO., INC. (US) | 1999-10-26 | — | — | US | disclosed |
| EP-0833633-A4 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO INC (US) | 1999-03-24 | — | — | EP | disclosed |
| WO-1999010525-A1 | A METHOD OF TREATING CANCER | MERCK & CO., INC. (US) | 1999-03-04 | — | — | WO | disclosed |
| WO-1999010524-A1 | A METHOD OF TREATING CANCER | MERCK & CO., INC. (US) | 1999-03-04 | — | — | WO | disclosed |
| WO-1999010523-A1 | A METHOD OF TREATING CANCER | MERCK & CO., INC. (US) | 1999-03-04 | — | — | WO | disclosed |
| US-5756528-A | ANTICARCINOGENIC AGENTS | MERCK & CO., INC. (US) | 1998-05-26 | — | — | US | disclosed |
| EP-0833633-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | Merck & Co., Inc. (US) | 1998-04-08 | — | — | EP | disclosed |
| WO-1996039137-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1996-12-12 | — | — | WO | disclosed |
| WO-1993011128-A1 | AMINOALKYLPYRROLIDINYLTHIOCARBAPENEM DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1993-06-10 | — | — | WO | disclosed |
| EP-0272456-B1 | 3-Pyrrolidinylthio-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid compounds and processes for the preparation thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1993-03-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140296237-A1 | PICOLINAMIDE DERIVATIVES AS TTX-S BLOCKERS | CACNA1G, SCN3A, SCN5A | NR1H2 2180/4885SRC 3918/4885ABCB1 600/4885 |
| US-20150274733-A1 | DIHYDROPYRROLIDINO-PYRIMIDINES AS KINASE INHIBITORS | MAP3K1, MAP3K2, BRAF | NR1H2 1113/4885SRC 200/4885ABCB1 680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.